Imatinib Teva

Imatinib, the active ingredient in Imatinib Teva, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It treats chronic myeloid leukemia and gastrointestinal stromal tumor in adult patients. It is indicated for patients with Philadelphia chromosome‑positive chronic myeloid leukemia and for those with KIT‑mutated gastrointestinal stromal tumors, providing targeted inhibition of malignant cell proliferation.

GNH USA supplies Imatinib Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, adhering to EU quality standards and providing reliable global logistics.

Imatinib is a tyrosine kinase inhibitor used to target specific oncogenic pathways in certain cancers.

- Chronic Myeloid Leukemia: achieves durable hematologic and cytogenetic responses in Philadelphia chromosome‑positive disease. - Gastrointestinal Stromal Tumor: induces tumor shrinkage and disease control in KIT‑mutated GIST. - Dermatofibrosarcoma Protuberans: provides tumor regression by inhibiting PDGFR signaling.

Adverse reactions may vary in frequency and severity.

Common Side Effects: - Nausea - Peripheral edema - Fatigue - Muscle cramps

Serious or Rare Side Effects: - Severe neutropenia or leukopenia - Hepatotoxicity with elevated transaminases - Cardiac failure or reduced left‑ventricular ejection fraction

Patients should be monitored regularly for safety and efficacy.

- Monitor blood counts: perform routine complete blood count assessments. - Assess liver function: check transaminases and bilirubin before and during therapy. - Evaluate cardiac status: monitor for signs of heart failure or reduced ejection fraction. - Avoid use in individuals with known hypersensitivity to imatinib or its excipients. - Store at ambient temperature: keep in the original container, protect from moisture and light.

Imatinib may interact with other medicines, altering its effectiveness or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase imatinib exposure. - Strong CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce imatinib exposure.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inhibitors (e.g., erythromycin, clarithromycin). - Warfarin: monitor INR for potential anticoagulation changes. - Digoxin: observe serum levels for possible increase.